nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Naratriptan—Feeling abnormal—Teniposide—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Naratriptan—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Naratriptan—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Naratriptan—Chills—Bleomycin—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Naratriptan—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Naratriptan—Sweating—Vincristine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Naratriptan—Nausea—Mechlorethamine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Naratriptan—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Naratriptan—Alopecia—Bleomycin—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Naratriptan—Haemoglobin—Carmustine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Naratriptan—Urticaria—Teniposide—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Naratriptan—Haemorrhage—Carmustine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Naratriptan—Body temperature increased—Teniposide—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Naratriptan—Erythema—Bleomycin—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Naratriptan—Paraesthesia—Fludarabine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Naratriptan—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Naratriptan—Hallucination—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Naratriptan—Sweating—Mitoxantrone—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Naratriptan—Dyspnoea—Fludarabine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Naratriptan—Ulcer—Methotrexate—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Naratriptan—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Naratriptan—Fatigue—Fludarabine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Naratriptan—Inflammation—Methotrexate—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Naratriptan—Hallucination—Vincristine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Naratriptan—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Naratriptan—Pain—Fludarabine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Naratriptan—Constipation—Fludarabine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Naratriptan—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Naratriptan—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Naratriptan—Hypersensitivity—Teniposide—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Naratriptan—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Naratriptan—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Naratriptan—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Naratriptan—Anaemia—Bleomycin—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Naratriptan—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Naratriptan—Asthenia—Teniposide—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Naratriptan—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Naratriptan—Malaise—Bleomycin—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Naratriptan—Pruritus—Teniposide—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Naratriptan—Arrhythmia—Carmustine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Naratriptan—Cystitis—Methotrexate—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Naratriptan—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Naratriptan—Cardiac disorder—Vincristine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Naratriptan—Alopecia—Carmustine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Naratriptan—Body temperature increased—Fludarabine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Naratriptan—Vaginal infection—Methotrexate—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Naratriptan—Erythema—Carmustine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Naratriptan—Cough—Bleomycin—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Naratriptan—Angiopathy—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Naratriptan—Diarrhoea—Teniposide—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Naratriptan—Myalgia—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Naratriptan—Alopecia—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Naratriptan—Discomfort—Bleomycin—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Naratriptan—Chills—Mitoxantrone—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Naratriptan—Bladder pain—Methotrexate—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Naratriptan—Urine output increased—Methotrexate—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Naratriptan—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Naratriptan—Alopecia—Mitoxantrone—lymphatic system cancer	0.002	0.002	CcSEcCtD
Naratriptan—Confusional state—Bleomycin—lymphatic system cancer	0.002	0.002	CcSEcCtD
Naratriptan—Vision blurred—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Naratriptan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Naratriptan—Tremor—Carmustine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Naratriptan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Naratriptan—Oedema—Bleomycin—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Naratriptan—Erythema—Mitoxantrone—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Naratriptan—Infection—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Naratriptan—Anaemia—Carmustine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Naratriptan—Vomiting—Teniposide—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Naratriptan—Agitation—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Naratriptan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Naratriptan—Asthenia—Fludarabine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Naratriptan—Rash—Teniposide—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Naratriptan—Dermatitis—Teniposide—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Naratriptan—Headache—Teniposide—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Naratriptan—Pruritus—Fludarabine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Naratriptan—Anaemia—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Naratriptan—Agitation—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Naratriptan—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Naratriptan—Polyuria—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Naratriptan—Photosensitivity—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Naratriptan—Hypotension—Bleomycin—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Naratriptan—Diarrhoea—Fludarabine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Naratriptan—Convulsion—Carmustine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Naratriptan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Naratriptan—Nausea—Teniposide—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Naratriptan—Anaemia—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Naratriptan—Vertigo—Vincristine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Naratriptan—Myalgia—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Naratriptan—Anxiety—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Naratriptan—Paraesthesia—Bleomycin—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Naratriptan—Malaise—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Naratriptan—Dyspnoea—Bleomycin—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Naratriptan—Convulsion—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Naratriptan—Confusional state—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Naratriptan—Oedema—Carmustine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Naratriptan—Myalgia—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Naratriptan—Cough—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Naratriptan—Infection—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Naratriptan—Vomiting—Fludarabine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Naratriptan—Convulsion—Mitoxantrone—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Naratriptan—Rash—Fludarabine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Naratriptan—Dermatitis—Fludarabine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Naratriptan—Pain—Bleomycin—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Naratriptan—Thrombocytopenia—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Naratriptan—Headache—Fludarabine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Naratriptan—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Naratriptan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Naratriptan—Myalgia—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Naratriptan—Anxiety—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Naratriptan—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Naratriptan—Discomfort—Mitoxantrone—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Naratriptan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Naratriptan—Oedema—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Naratriptan—Infection—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Naratriptan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Naratriptan—Confusional state—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Naratriptan—Nervous system disorder—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Naratriptan—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Naratriptan—Hypotension—Carmustine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Naratriptan—Oedema—Mitoxantrone—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Naratriptan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Naratriptan—Nausea—Fludarabine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Naratriptan—Infection—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Naratriptan—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Naratriptan—Shock—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Naratriptan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Naratriptan—Urticaria—Bleomycin—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Naratriptan—Body temperature increased—Bleomycin—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Naratriptan—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Naratriptan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Naratriptan—Paraesthesia—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Naratriptan—Hypotension—Vincristine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Naratriptan—Dyspnoea—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Naratriptan—Somnolence—Carmustine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Naratriptan—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Naratriptan—Hypotension—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Naratriptan—Paraesthesia—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Naratriptan—Pain—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Naratriptan—Constipation—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Naratriptan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Naratriptan—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Naratriptan—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Naratriptan—Somnolence—Mitoxantrone—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Naratriptan—Feeling abnormal—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Naratriptan—Fatigue—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Naratriptan—Asthenia—Bleomycin—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Naratriptan—Pain—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Naratriptan—Constipation—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Naratriptan—Asthma—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Naratriptan—Pruritus—Bleomycin—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Naratriptan—Fatigue—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Naratriptan—Constipation—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Naratriptan—Pain—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Naratriptan—Body temperature increased—Carmustine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Naratriptan—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Naratriptan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Naratriptan—Body temperature increased—Vincristine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Naratriptan—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Naratriptan—Urticaria—Mitoxantrone—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Naratriptan—Hypersensitivity—Carmustine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Naratriptan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Naratriptan—Pneumonia—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Naratriptan—Vomiting—Bleomycin—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Naratriptan—Drowsiness—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Naratriptan—Depression—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Naratriptan—Rash—Bleomycin—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Naratriptan—Dermatitis—Bleomycin—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Naratriptan—Asthenia—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Naratriptan—Hypersensitivity—Vincristine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Naratriptan—Sweating—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Naratriptan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Naratriptan—Asthenia—Vincristine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Naratriptan—Diarrhoea—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Naratriptan—Nausea—Bleomycin—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Naratriptan—Asthenia—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Naratriptan—Dizziness—Carmustine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Naratriptan—Haemoglobin—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Naratriptan—Diarrhoea—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Naratriptan—Haemorrhage—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Naratriptan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Naratriptan—Vomiting—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Naratriptan—Dizziness—Vincristine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Naratriptan—Rash—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Naratriptan—Dermatitis—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Naratriptan—Headache—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Naratriptan—Tinnitus—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Naratriptan—Vomiting—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Naratriptan—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Naratriptan—Rash—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Naratriptan—Dermatitis—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Naratriptan—Headache—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Naratriptan—Nausea—Carmustine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Naratriptan—Angiopathy—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Naratriptan—Vomiting—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Naratriptan—Immune system disorder—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Naratriptan—Rash—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Naratriptan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Naratriptan—Chills—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Naratriptan—Headache—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Naratriptan—Alopecia—Methotrexate—lymphatic system cancer	0.000999	0.000999	CcSEcCtD
Naratriptan—Erythema—Methotrexate—lymphatic system cancer	0.000984	0.000984	CcSEcCtD
Naratriptan—Nausea—Vincristine—lymphatic system cancer	0.000983	0.000983	CcSEcCtD
Naratriptan—Nausea—Mitoxantrone—lymphatic system cancer	0.000957	0.000957	CcSEcCtD
Naratriptan—Vision blurred—Methotrexate—lymphatic system cancer	0.000927	0.000927	CcSEcCtD
Naratriptan—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000913	0.000913	CcSEcCtD
Naratriptan—Anaemia—Methotrexate—lymphatic system cancer	0.000909	0.000909	CcSEcCtD
Naratriptan—Malaise—Methotrexate—lymphatic system cancer	0.000887	0.000887	CcSEcCtD
Naratriptan—Vertigo—Methotrexate—lymphatic system cancer	0.000884	0.000884	CcSEcCtD
Naratriptan—Cough—Methotrexate—lymphatic system cancer	0.000859	0.000859	CcSEcCtD
Naratriptan—Convulsion—Methotrexate—lymphatic system cancer	0.000853	0.000853	CcSEcCtD
Naratriptan—Myalgia—Methotrexate—lymphatic system cancer	0.000838	0.000838	CcSEcCtD
Naratriptan—Arthralgia—Methotrexate—lymphatic system cancer	0.000838	0.000838	CcSEcCtD
Naratriptan—Discomfort—Methotrexate—lymphatic system cancer	0.000828	0.000828	CcSEcCtD
Naratriptan—Confusional state—Methotrexate—lymphatic system cancer	0.00081	0.00081	CcSEcCtD
Naratriptan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000803	0.000803	CcSEcCtD
Naratriptan—Infection—Methotrexate—lymphatic system cancer	0.000798	0.000798	CcSEcCtD
Naratriptan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000788	0.000788	CcSEcCtD
Naratriptan—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000786	0.000786	CcSEcCtD
Naratriptan—Skin disorder—Methotrexate—lymphatic system cancer	0.00078	0.00078	CcSEcCtD
Naratriptan—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000776	0.000776	CcSEcCtD
Naratriptan—Hypotension—Methotrexate—lymphatic system cancer	0.00075	0.00075	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000732	0.000732	CcSEcCtD
Naratriptan—Paraesthesia—Methotrexate—lymphatic system cancer	0.000721	0.000721	CcSEcCtD
Naratriptan—Dyspnoea—Methotrexate—lymphatic system cancer	0.000716	0.000716	CcSEcCtD
Naratriptan—Somnolence—Methotrexate—lymphatic system cancer	0.000714	0.000714	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000693	0.000693	CcSEcCtD
Naratriptan—Fatigue—Methotrexate—lymphatic system cancer	0.000692	0.000692	CcSEcCtD
Naratriptan—Pain—Methotrexate—lymphatic system cancer	0.000687	0.000687	CcSEcCtD
Naratriptan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000662	0.000662	CcSEcCtD
Naratriptan—Urticaria—Methotrexate—lymphatic system cancer	0.000638	0.000638	CcSEcCtD
Naratriptan—Body temperature increased—Methotrexate—lymphatic system cancer	0.000635	0.000635	CcSEcCtD
Naratriptan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000592	0.000592	CcSEcCtD
Naratriptan—Asthenia—Methotrexate—lymphatic system cancer	0.000576	0.000576	CcSEcCtD
Naratriptan—Pruritus—Methotrexate—lymphatic system cancer	0.000568	0.000568	CcSEcCtD
Naratriptan—Diarrhoea—Methotrexate—lymphatic system cancer	0.000549	0.000549	CcSEcCtD
Naratriptan—Dizziness—Methotrexate—lymphatic system cancer	0.000531	0.000531	CcSEcCtD
Naratriptan—Vomiting—Methotrexate—lymphatic system cancer	0.000511	0.000511	CcSEcCtD
Naratriptan—Rash—Methotrexate—lymphatic system cancer	0.000506	0.000506	CcSEcCtD
Naratriptan—Dermatitis—Methotrexate—lymphatic system cancer	0.000506	0.000506	CcSEcCtD
Naratriptan—Headache—Methotrexate—lymphatic system cancer	0.000503	0.000503	CcSEcCtD
Naratriptan—Nausea—Methotrexate—lymphatic system cancer	0.000477	0.000477	CcSEcCtD
